Abstract 1571P
Background
In France, oncology is one of the disciplines for which the percentage of residents reorientating at the start of internship towards another specialty is the highest (8-10%). The determinants of this reorientation are unknown.
Methods
We conducted a quantitative online survey with the 121 interns of the 2022-2023 class during their 1st year of oncology training, with 2 follow-ups over 2 months. 36 potential determinants from previous works (Wright et al. 2004; Beaulieu et al. 2010) were evaluated using a 5-point Likert scale alongside parameters describing the resident. We also assessed their satisfaction with the teaching received. We conducted univariate and multivariate linear regression analyses.
Results
The response rate was 107/121 (88.5%), but 99 questionnaires were usable for the determinants analysis (81.2%). 9 residents were considering or may consider changing speciality. In multivariate analysis, 3 factors were associated with considering a change of specialty: “desire for social commitment” (β=2.15, p=.025), “other experience during the 2 nd -cycle hospital traineeships” (β=3.64, p<.001) and “interest in emergency care” (β=2.13, p=.028). Satisfaction with the education received was negatively associated with the desire to change specialty (β=-3.49, p<.001). The determinants of satisfaction in oncology training were: “being able to move to the desired university” (β=4.24, p=.016), “an image of dynamism of oncology” (β=4.68, p<.001); on the other hand, the “desire for short training” was negatively associated with satisfaction with oncology training (β=0.281, p=.042).
Conclusions
We identified 2 intrinsic factors (social commitment and interest in emergency care) and 2 extrinsic factors (other significant experiences during 2nd-cycles hospital traineeships and low satisfaction in oncology training) as being able to explain the wish of reorientation among oncology residents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10